Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers

BACKGROUND: Dyslipidemia and type 2 diabetes are two of the most significant risk factors for the development of cardiovascular disease. Measurement of lipoprotein subclasses provides important information about derangements in lipid metabolism and helps refine cardiovascular risk assessment. Exenat...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiquette, Elaine, Toth, Peter P, Ramirez, Gilbert, Cobble, Michael, Chilton, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3500143/
https://www.ncbi.nlm.nih.gov/pubmed/23166441
http://dx.doi.org/10.2147/VHRM.S37969

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3500143/
https://www.ncbi.nlm.nih.gov/pubmed/23166441
http://dx.doi.org/10.2147/VHRM.S37969

Ejemplares similares